TP53 and cancer: In addition, most cancer cells with p53 mutation showed resistant to TKIs in CCLE database41, suggesting that wild-type p53 might sensitize cells to TKIs and transcriptional repression of SCD1 by p53 might be one of the mechanisms (Supplementary Fig. 6g–i).